PrIMAVeRa Mid-term Review held in April 2025
- europevaccine
- Apr 10
- 2 min read
April 2025
Great news out of PrIMAVeRa: the project achieved a significant project milestone by completing the mid-term review, presenting project progress for a panel of external experts during a virtual meeting held on 02 April. Through the course of the full-day meeting, leaders of the project’s activities detailed their research and outputs to provide a complete overview of the current state of the project.
The topics covered:
Results of the systematic reviews on the burden of antimicrobial disease
Results of the systematic review on existing AMR models
Progress and preliminary analysis of individual-level patient data collected to-date
Progress made on cost-effectiveness models in development to evaluate the effects of vaccines and monoclonal antibodies on antimicrobial resistance (AMR)
Ongoing and future plans for data acquisition, model validation, and sustainability of project outputs
Project management and coordination structure and execution
Communication strategy and activities
Project outlook and sustainability
Partners benefitted from Q&A exchanges with the external experts, gaining valuable insights and suggestions to inform further actions within the project. Consortium members will also receive a full report comprehensively detailing reviewer feedback and recommendations, to further enable effective research and effort.
The review ended with positive initial feedback from reviewers, who applauded the work done so far by PrIMAVeRa researchers and expressed positivity for the future of the project. Recommendations were made regarding data collection and handling of data already collected, as well as additional considerations for modelling approaches. PrIMAVeRa partners are pleased by this positive reception and encouragement to continue in the fight against antimicrobial resistance.
This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420 (PrIMAVeRa). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and
innovation programme and EFPIA. www.imi.europa.eu
This communication reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.
